Immune Transfer Studies in Canine Allogeneic Marrow Graft Donor-Recipient Pairs

Grosse‐Wilde, H.; Krumbacher, K.; Schüning, F.; Doxiadis, Ilias; Hk, Mahmoud; Emde, C; Schmidt-Weinmar, Annette; Uw, Schaefer

doi:10.1097/00007890-198607000-00014

Cited by 10 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our former studies in a preclinical model of the dog showed a successful transfer of functionally active B and T cells with memory toward recall antigens as facilitated by allogeneic HCT (1). In men, the feasibility of a transfer of humoral immunity (e.g., against tetanus toxoid or hepatitis B virus [HBV]) by stem-cell grafting or peripheral blood lymphocyte injection has also been demonstrated (2)(3)(4)(5).…”

mentioning

confidence: 99%

Transfer of humoral and cellular hepatitis B immunity by allogeneic hematopoietic cell transplantation

et al. 2003

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Transfer of humoral and cellular hepatitis B immunity by allogeneic hematopoietic cell transplantation

et al. 2003

View full text Add to dashboard Cite

show abstract

“…This strategy may offer the opportunity to target potential yet undefined lymphoma antigens (other than idiotype), therefore widening the T-cell repertoire against lymphoma. Another approach to idiotype vaccination for nonHodgkin's lymphoma is based on animal and human studies, which have shown that, in an allogeneic setting, immunity to certain antigens could be transferred from the marrow donor to the patient [124][125][126][127]. The strategy entails the immunization of the immunologically competent and normal allogeneic donor with the idiotype vaccine derived from the recipient's tumor before harvesting the stem cells to be used in the transplant.…”

mentioning

confidence: 99%

Cancer Vaccines

Espinoza‐Delgado

2002

The Oncologist

View full text Add to dashboard Cite

Although cancer immunotherapy was initiated byWilliam Coley more than a century ago, the field of cancer vaccines is in an early stage of development. Only recently, major advances in cellular and molecular immunology have allowed a comprehensive understanding of the complex and high rate of interactions between the immune system and tumor cells. We have learned that these tumor-immune system interactions may result either in strong immune antitumor response or tolerance to tumor-associated antigens. This article will discuss the profound interest in cancer vaccines derived from their potential to induce antitumor responses in vivo. Substantial data from several preclinical models and early human clinical trials have confirmed the ability of cancer vaccines to induce immune responses that are tumor-specific and, in some cases, associated with clinical responses. One future challenge will be to determine how to appropriately stimulate the pathways leading to effective interaction among antigen-presenting cells, T lymphocytes, and tumor cells. It also is critical to develop monitoring strategies that may allow the identification of patients who may benefit from cancer vaccines. The Oncologist 2002;7(suppl 3):20-33 The Oncologist 2002;7(suppl3):20-33 www.TheOncologist.com

show abstract

Non-Hodgkin’s Lymphoma

Espinoza‐Delgado¹,

Longo²

2003

Allogeneic Stem Cell Transplantation

View full text Add to dashboard Cite

Immune Transfer Studies in Canine Allogeneic Marrow Graft Donor-Recipient Pairs

Cited by 10 publications

References 0 publications

Transfer of humoral and cellular hepatitis B immunity by allogeneic hematopoietic cell transplantation

Transfer of humoral and cellular hepatitis B immunity by allogeneic hematopoietic cell transplantation

Cancer Vaccines

Non-Hodgkin’s Lymphoma

Contact Info

Product

Resources

About